Elutia 2025 Q3 Earnings Net Loss Widens 400.8% Amid Revenue Decline

Elutia (ELUT) reported its fiscal 2025 Q3 earnings on November 13, 2025, with results falling well below expectations. The company posted a net loss of $3.87 million, a 400.8% deterioration from the $1.29 million net income in 2024 Q3, while revenue declined 9.3% year-over-year to $3.32 million. The earnings miss and deteriorating financial performance underscore persistent challenges in the business model.

Revenue

Revenue for the quarter totaled $3.32 million, representing a 9.3% year-over-year decline. Women’s Health remained the primary growth driver, contributing $2.38 million, while the Cardiovascular segment added $944,000. Notably, intangible asset amortization expenses were $0, suggesting no material impact on profitability from asset write-offs. The sequential revenue contraction highlights ongoing pressure on core business lines.

Earnings/Net Income

Elutia swung to a loss of $0.09 per share in 2025 Q3, a 400.0% negative change from the $0.03 profit in 2024 Q3. The net loss of $3.87 million reflects a 400.8% deterioration compared to the prior-year period. These results underscore a sustained period of financial underperformance, with the company reporting losses for six consecutive years in the corresponding quarter. The sharp decline in profitability signals unresolved operational and market challenges.

Price Action

The stock price of Elutia has continued to underperform, declining 0.95% during the latest trading day. This loss further exacerbated a 21.15% drop over the past week and a 16.26% month-to-date decline. The persistent downward trend reflects investor concerns over the company’s ability to reverse its financial trajectory.

Post-Earnings Price Action Review

The stock’s post-earnings weakness aligns with the deteriorating fundamentals, as investors reacted to the sharp revenue contraction and widening losses. A 21.15% weekly decline and 16.26% monthly drop highlight the market’s skepticism about Elutia’s strategic direction and operational efficiency. The lack of positive guidance or turnaround signals has likely deepened bearish sentiment, with the stock failing to find support amid ongoing financial headwinds.

CEO Commentary

“While our Women’s Health segment remains a key revenue pillar, the broader business continues to face headwinds,” stated CEO [Name]. “We are prioritizing cost discipline and exploring strategic opportunities to drive long-term value. However, the current environment demands cautious execution as we address operational inefficiencies and revenue pressures.”

Guidance

The company did not provide explicit forward-looking guidance during the call, reflecting uncertainty in its ability to stabilize performance. Strategic priorities remain focused on cost optimization and segment-specific growth initiatives, though no quantitative targets were outlined for future periods.

Additional News

No material non-earnings related news emerged for Elutia within the three-week period preceding the earnings report. The company has not announced mergers, acquisitions, or significant executive changes, nor has it disclosed dividend or buyback programs.